Quantum Computing Inc.
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
The weakest and most contested moat of the quantum pure-plays — a photonic/TFLN foundry thesis backed by ~$1.4B of cash but almost no organic revenue, acquisition-manufactured growth, and an active short-seller report alleging the foundry business is 'phantom.' A cash-rich option on photonic quantum, not yet a demonstrated business.
QUBT's case is a cash pile and a technology claim more than a proven franchise — and one pillar is publicly disputed. Three early, unproven pillars:
- Photonic / TFLN Technology: QUBT's bet is thin-film lithium niobate photonics — chips and foundry services, Dirac entropy-computing machines, the EmuCore reservoir-computing device, and quantum cybersecurity. Photonics is a legitimate quantum modality, but QUBT's specific claims are early-stage and, unlike IonQ or D-Wave, are not yet backed by material revenue or independent, at-scale validation.
- Cash-Funded Acquisitions: With ~$1.4B raised, QUBT has bought Lumina Semiconductor (~$110M), NuCrypt (~$5M), and NHanced Semiconductors (~$73M + earnout) to assemble a photonics/packaging stack. This is buying capability, not compounding a moat — the acquisitions inflate reported revenue but the organic business remains de minimis, and integrating disparate assets is itself a risk.
- Early Customer & Government Touchpoints: A NASA subcontract (~$406K), a first quantum-cybersecurity sale to a top-5 US bank, an EmuCore sale to an automotive OEM, and a vibrometer sale to TU Delft are cited as validation. These are small, one-off touchpoints rather than a recurring book — and short-seller Iceberg Research has publicly questioned the reality and timing of some announced orders.
Moat Verdict
What durability QUBT can claim — scarce photonics/TFLN talent and any genuine foundry process IP — is AI-resilient, since AI cannot replicate the underlying fabrication physics. But the honest picture is that QUBT has the thinnest moat of the quantum pure-plays: most categories are N/A or weakened, organic revenue is de minimis (~$682K FY2025), headline growth is acquisition-manufactured, and an active Iceberg Research short report specifically disputes the reality of the foundry business and some announced orders. The ~$1.4B cash balance is real and provides a partial floor, but the operating thesis is unproven and contested. This is a cash-rich, high-risk option on photonic quantum — the lowest-conviction name of the four and one where the credibility questions must be resolved before the business can be underwritten.
40.4 resilient · 35.0 vulnerable · 80/20 = 39.3 · = 39
Open a moat to read its note.
QUBT sells hardware, foundry services, and devices; there is no complex, high-switching-cost software interface customers master over years.
QUBT's software/algorithms (e.g. Dirac, EmuCore tooling) are early and not embedded as proprietary business logic in customers' core workflows — no meaningful lock-in demonstrated.
QUBT does not monetise gated access to a public dataset.
Photonics and TFLN engineering is genuinely scarce and AI-resilient, and QUBT has acquired teams (Lumina, NuCrypt) to build it — but depth and retention are unproven versus better-capitalised peers, so this is present rather than a strong, demonstrated advantage.
QUBT is assembling a photonics/packaging stack via acquisitions, but the pieces are not yet integrated into a sticky bundle — this is capability-buying, not an emergent lock-in.
TFLN foundry process IP is claimed as proprietary, but with de minimis production and disputed order history there is little evidence of a compounding, monetised data or process advantage.
A small NASA subcontract and early government touchpoints exist, but QUBT lacks the DARPA/DOE/CHIPS-scale federal pedigree of its peers — government lock-in is minimal at this stage.
an additional foundry or device customer does not make the platform more valuable to others; there is no network dynamic.
QUBT does not sit in a payment or transaction layer of customers' daily operations.
it is not the authoritative record for any external business function.
Pre-scale business: no unit-cost lead exists yet, and none is credited on a roadmap.
No brand premium: customers buy on capability and price, and the name has not yet been tested through a cycle.
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
The weakest and most contested moat of the quantum pure-plays — a photonic/TFLN foundry thesis backed by ~$1.4B of cash but almost no organic revenue, acquisition-manufactured growth, and an active short-seller report alleging the foundry business is 'phantom.' A cash-rich option on photonic quantum, not yet a demonstrated business.
Growth Score
QUBT is the hardest quantum pure-play to underwrite honestly. Q2 2026 revenue was $5.6M (vs $61K a year earlier and $3.7M in Q1), but almost all of it is consolidated from acquired photonics businesses — Luminar Semiconductor (LSI, acquired during Q1 for $110M) and NuCrypt — rather than organic demand; FY2025 organic revenue was roughly $682K. In Q2 it also closed the $73.1M NHanced Semiconductors deal (up to $72M more in earn-outs), which brings an operating advanced-packaging foundry and makes it Fab 2, and contract backlog rose to ~$42.5M from ~$16M. The company is cash-rich (~$1.3B) and the thesis is that TFLN photonic-chip fabrication and foundry services eventually generate real revenue — but short-seller Iceberg Research has alleged the foundry business 'will amount to nothing' and that some announced orders are exaggerated. Growth here is an option on cash deployment through acquisitions, not a demonstrated organic trajectory.
Valuation Score
At ~$8 (~$1.8B) QUBT trades at roughly 2,700× trailing revenue — the most extreme valuation-to-fundamentals ratio in the group — but with ~$1.4B of cash (~$6.2/share) providing an unusually large partial floor. The price sits just above our $7 base case and only a fraction of the way into an $18 bull case (near the thin ~$18 average target from ~6 analysts). The cash is real; almost everything above it is a bet that the disputed photonic-foundry thesis becomes a genuine business. Given the active short report and near-nil organic revenue, treat this as the lowest-conviction name of the four.
The Contested Foundry Bet
QUBT's case is a cash pile and a technology claim more than a proven franchise — and one pillar is publicly disputed. Three early, unproven pillars:
- Photonic / TFLN Technology: QUBT's bet is thin-film lithium niobate photonics — chips and foundry services, Dirac entropy-computing machines, the EmuCore reservoir-computing device, and quantum cybersecurity. Photonics is a legitimate quantum modality, but QUBT's specific claims are early-stage and, unlike IonQ or D-Wave, are not yet backed by material revenue or independent, at-scale validation.
- Cash-Funded Acquisitions: With ~$1.4B raised, QUBT has bought Lumina Semiconductor (~$110M), NuCrypt (~$5M), and NHanced Semiconductors (~$73M + earnout) to assemble a photonics/packaging stack. This is buying capability, not compounding a moat — the acquisitions inflate reported revenue but the organic business remains de minimis, and integrating disparate assets is itself a risk.
- Early Customer & Government Touchpoints: A NASA subcontract (~$406K), a first quantum-cybersecurity sale to a top-5 US bank, an EmuCore sale to an automotive OEM, and a vibrometer sale to TU Delft are cited as validation. These are small, one-off touchpoints rather than a recurring book — and short-seller Iceberg Research has publicly questioned the reality and timing of some announced orders.
Moat Verdict
What durability QUBT can claim — scarce photonics/TFLN talent and any genuine foundry process IP — is AI-resilient, since AI cannot replicate the underlying fabrication physics. But the honest picture is that QUBT has the thinnest moat of the quantum pure-plays: most categories are N/A or weakened, organic revenue is de minimis (~$682K FY2025), headline growth is acquisition-manufactured, and an active Iceberg Research short report specifically disputes the reality of the foundry business and some announced orders. The ~$1.4B cash balance is real and provides a partial floor, but the operating thesis is unproven and contested. This is a cash-rich, high-risk option on photonic quantum — the lowest-conviction name of the four and one where the credibility questions must be resolved before the business can be underwritten.
40.4 resilient · 35.0 vulnerable · 80/20 = 39.3 · = 39
Open a moat to read its note.
QUBT sells hardware, foundry services, and devices; there is no complex, high-switching-cost software interface customers master over years.
QUBT's software/algorithms (e.g. Dirac, EmuCore tooling) are early and not embedded as proprietary business logic in customers' core workflows — no meaningful lock-in demonstrated.
QUBT does not monetise gated access to a public dataset.
Photonics and TFLN engineering is genuinely scarce and AI-resilient, and QUBT has acquired teams (Lumina, NuCrypt) to build it — but depth and retention are unproven versus better-capitalised peers, so this is present rather than a strong, demonstrated advantage.
QUBT is assembling a photonics/packaging stack via acquisitions, but the pieces are not yet integrated into a sticky bundle — this is capability-buying, not an emergent lock-in.
TFLN foundry process IP is claimed as proprietary, but with de minimis production and disputed order history there is little evidence of a compounding, monetised data or process advantage.
A small NASA subcontract and early government touchpoints exist, but QUBT lacks the DARPA/DOE/CHIPS-scale federal pedigree of its peers — government lock-in is minimal at this stage.
an additional foundry or device customer does not make the platform more valuable to others; there is no network dynamic.
QUBT does not sit in a payment or transaction layer of customers' daily operations.
it is not the authoritative record for any external business function.
Pre-scale business: no unit-cost lead exists yet, and none is credited on a roadmap.
No brand premium: customers buy on capability and price, and the name has not yet been tested through a cycle.
Growth Analysis
Growth Drivers
Key Risk
QUBT carries specific, unresolved credibility risk: short-seller Iceberg Research has alleged in its 'Phantom Chip Foundry' reports that the TFLN foundry pivot is a rebrand of a long-running 'perma-scam' and that certain announced orders are false or exaggerated and timed around capital raises. Even setting the allegations aside, organic revenue is de minimis, so if the foundries fail to generate real, verifiable revenue there is little fundamental support beneath the stock beyond its cash. This is the quantum cohort's shared risk — commercially useful fault tolerance arriving later than priced — graded by exposure: QCi's quantum products have no revenue base to fall back on, so it stays severe with IonQ and Rigetti.
Score Derivation
72.9 base − 1.3 trajectory − 4 margin − 15 risk = 53
Base 72.9 (5–15% CAGR, midpoint 10%, an organic rate for the acquired photonics base — the ~+9,000% YoY acquisition lap is not carried) − 1.3 trajectory (acquired photonics and foundry stable; organic quantum products decelerating: (0 − 1) / 3 × 4) − 4 compressing margin (net loss widened from $4.1M in Q1 to $11.8M in Q2 2026; Fab 1 gross margins held down by under-utilisation) − 15 severe risk. The acquired-revenue driver moves from accelerating to stable: Q2's +50% QoQ reflects LSI being consolidated for only part of Q1, not organic demand. Severity stays severe with IONQ and RGTI on the shared fault-tolerance-timing risk, compounded by the short-seller allegations. The formula computed 54 on the old inputs = 53
Price Scenarios (12–24 Months)
Valuation Analysis
P/E is omitted — QUBT is loss-making (Q1 2026 net loss $4.1M; a prior-year 'profit' was a non-cash warrant gain) with de minimis revenue. Conventional sales multiples are almost meaningless at ~2,700× trailing; the more relevant frame is price-to-cash (~$1.8B cap vs ~$1.4B cash), which implies the market ascribes only a modest premium to the operating business itself. That premium, however, is exactly what short-sellers dispute. $7 (base) — near the ~$6.2/share cash value; the operating business carries little demonstrable worth until the foundry produces verifiable revenue.
Where We Are vs Targets
Loading live price…
The foundry thesis fails to produce verifiable revenue, short-seller allegations gain traction, and the stock compresses toward — or through — its cash value as dilution continues and confidence erodes.
- Fab-1/Fab-2 foundry revenue fails to materialise at scale, validating the 'phantom foundry' critique
- Further scrutiny of announced orders and continued equity issuance pressures the stock toward its ~$6/share cash value and below on lost confidence
- Acquisition integration disappoints, and headline revenue growth is revealed as purely inorganic
QUBT deploys its cash into the foundry and acquisitions, generates modest but real revenue, and the market values it at roughly its cash plus a small operating premium — the stock drifts near current levels amid persistent skepticism.
- The TFLN foundry and acquired businesses produce some verifiable, recurring revenue, partially answering the credibility questions
- The ~$1.4B cash balance anchors the valuation while the operating business is slowly built out
- No major adverse resolution of the short-seller allegations, but no decisive vindication either
The photonic-foundry bet is vindicated: Fab-1/Fab-2 win real foundry customers, the acquisitions integrate into a coherent photonics stack, and the market re-rates QUBT as a legitimate photonic-quantum and TFLN play toward the thin analyst target.
- TFLN foundry services sign verifiable, recurring commercial customers at meaningful volume
- Lumina, NuCrypt, and NHanced integrate into a credible end-to-end photonics/packaging platform
- Independent validation and audited revenue growth decisively rebut the short-seller thesis, unlocking a re-rating